Virologica Sinica

, Volume 30, Issue 1, pp 45–51 | Cite as

Molecular dissection of phage lysin PlySs2: integrity of the catalytic and cell wall binding domains is essential for its broad lytic activity

  • Yanling Huang
  • Hang Yang
  • Junping Yu
  • Hongping WeiEmail author
Research Article


The novel phage lysin PlySs2, is reported to be highly active against various bacteria, including staphylococci, streptococci and Listeria. However, the molecular mechanisms underlying its broad lytic spectrum remain to be established. In the present study, the lytic activity of the catalytic domain (CD, PlySc) and binding specificity of the cell wall binding domain (CBD, PlySb) of PlySs2 were examined. Our results showed that PlySc alone maintains very limited lytic activity. Enhanced green fluorescent protein (EGFP)-fused PlySb displayed high binding affinity to the streptococcal strains tested, including S. suis, S. dysgalactiae, and S. agalactiae, but not staphylococci, supporting its utility as a good CBD donor for streptococcal-targeted lysin engineering. EGFP-fused intact PlySs2 similarly displayed high affinity for streptococci, but not staphylococci. Notably, four truncated PlySb fragments showed no binding capacity. These findings collectively indicate that integrity of the PlySc and PlySb domains is an essential determinant of the broad lytic activity of PlySs2.


streptococci lysin cell wall binding domain catalytic domain bacterial resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahluwalia AK, Sekhon BS. 2012. Enzybiotics: A promising approach to fight infectious diseases and an upcoming need for future. J Pharm Educ Res, 3: 42–51.Google Scholar
  2. Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay JP, Defraine V, Michiels J, Cenens W, Aertsen A, Miller S, Lavigne R. 2014. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 58: 3774–3784.CrossRefPubMedCentralPubMedGoogle Scholar
  3. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay JP, Miller S, Volckaert G, Lavigne R. 2014. Engineered endolysin-based “artilysins” to combat multidrug-resistant gram-negative pathogens. MBio, 5: e01379–14.CrossRefPubMedCentralPubMedGoogle Scholar
  4. Coello R, Jimenez J, Garcia M, Arroyo P, Minguez D, Fernandez C, Cruzet F, Gaspar C. 1994. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur J Clin Microbiol Infect Dis, 13: 74–81.CrossRefPubMedGoogle Scholar
  5. De Lencastre H, Kristinsson KG, Brito-Avo A, Sanches IS, Sa-Leao R, Saldanha J, Sigvaldadottir E, Karlsson S, Oliveira D, Mato R, Aires de Sousa M, Tomasz A. 1999. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb Drug Resist, 5: 19–29.CrossRefPubMedGoogle Scholar
  6. Dong Q, Wang J, Yang H, Yu J, Zhang Y, Huang Y, Zhang XE, Wei H. 2014. Construction of a Chimeric Lysin Ply187N-V12C with Extended Lytic Activity against Staphylococci and Streptococci. Microb Biotechnol, 1–11.Google Scholar
  7. Fischetti VA. 2003. Novel method to control pathogenic bacteria on human mucous membranes. Ann N Y Acad Sci, 987: 207–214.CrossRefPubMedGoogle Scholar
  8. Fischetti VA. 2010. Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol, 300: 357–362.CrossRefPubMedCentralPubMedGoogle Scholar
  9. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 57: 2743–2750.CrossRefPubMedCentralPubMedGoogle Scholar
  10. Junjappa RP, Desai SN, Roy P, Narasimhaswamy N, Raj JR, Durgaiah M, Vipra A, Bhat UR, Satyanarayana SK, Shankara N, Basingi SM, Bhat JJ, Hariharan S, Sriram B, Padmanabhan S. 2013. Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma: potential applications. Vet Res Commun, 37: 217–228.CrossRefPubMedGoogle Scholar
  11. Loessner MJ, Gaeng S, Scherer S. 1999. Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187. J Bacteriol, 181: 4452–4460.PubMedCentralPubMedGoogle Scholar
  12. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, Noinaj N, Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan SK. 2012. Structural engineering of a phage lysin that targets gram-negative pathogens. Proc Natl Acad Sci U S A, 109: 9857–9862.CrossRefPubMedCentralPubMedGoogle Scholar
  13. Mao J, Schmelcher M, Harty WJ, Foster-Frey J, Donovan DM. 2013. Chimeric Ply187 endolysin kills Staphylococcus aureusmore effectively than the parental enzyme. FEMS Microbiol Lett, 342: 30–36.CrossRefPubMedCentralPubMedGoogle Scholar
  14. McGowan S, Buckle AM, Mitchell MS, Hoopes JT, Gallagher DT, Heselpoth RD, Shen Y, Reboul CF, Law RH, Fischetti VA, Whisstock JC, Nelson DC. 2012. X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proc Natl Acad Sci U S A, 109: 12752–12757.CrossRefPubMedCentralPubMedGoogle Scholar
  15. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006. PlyC: A multimeric bacteriophage lysin. Proc Natl Acad Sci U S A, 103: 10765–10770.CrossRefPubMedCentralPubMedGoogle Scholar
  16. O’Flaherty S, Ross RP, Coffey A. 2009. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev, 33: 801–819.CrossRefPubMedGoogle Scholar
  17. Pastagia M, Schuch R, Fischetti VA, Huang DB. 2013. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol, 62: 1506–1516.CrossRefPubMedGoogle Scholar
  18. Schuch R, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, Fischetti VA, Huang DB, Nowinski RC, Wittekind M. 2014. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis, 209: 1469–1478.CrossRefPubMedCentralPubMedGoogle Scholar
  19. Singh PK, Donovan DM, Kumar A. 2014. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob Agents Chemother, 58: 4621–4629.CrossRefPubMedCentralPubMedGoogle Scholar
  20. Veiga-Crespo P, Ageitos JM, Poza M, Villa TG. 2007. Enzybiotics: A look to the future, recalling the past. J Pharm Sci, 96: 1917–1924.CrossRefPubMedGoogle Scholar
  21. Villa TG, Crespo PV eds. 2010. Enzybiotics: Antibiotic enzymes as drugs and therapeutics. Hoboken, New Jersey: John Wiley & Sons, pp107–122.Google Scholar
  22. Yang H, Yu J, Wei H. 2014a. Engineered bacteriophage lysins as novel anti-infectives. Front Microbiol, 5: 542.PubMedCentralPubMedGoogle Scholar
  23. Yang H, Zhang Y, Yu J, Huang Y, Zhang XE, Wei H. 2014b. Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother, 58: 536–542.CrossRefPubMedCentralPubMedGoogle Scholar
  24. Yang H, Wang DB, Dong Q, Zhang Z, Cui Z, Deng J, Yu J, Zhang XE, Wei H. 2012. Existence of separate domains in lysin PlyG for recognizing Bacillus anthracis spores and vegetative cells. Antimicrob Agents Chemother, 56: 5031–5039.CrossRefPubMedCentralPubMedGoogle Scholar
  25. Yoong P, Schuch R, Nelson D, Fischetti VA. 2004. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol, 186: 4808–4812.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Yanling Huang
    • 1
  • Hang Yang
    • 1
  • Junping Yu
    • 1
  • Hongping Wei
    • 1
    Email author
  1. 1.Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina

Personalised recommendations